熱門資訊> 正文
因监管不确定性，贝尔德的Neurogene评级下调至中立
2025-05-16 23:18
- Neurogene, Inc. - Common Stock(NGNE) 0
- Taysha Gene Therapies, Inc.(TSHA) 0
- NEOLEUKIN THERAPEUTICS INC(NLTX) 0
- Neurogene (NASDAQ:NGNE) was downgraded to Neutral from Outperform at Baird, citing increasing regulatory uncertainty and a higher approval bar at the FDA under new leadership.
- The analysts at Baird said that despite the stock rebound since April, they believe the FDA's bar for approval is indeed moving higher, as former head of Center for Biologics Evaluation and Research, Peter Marks, has been replaced by a far more data-driven Vinay Prasad.
- Refering to Taysha Gene Therapies's (TSHA) recent data, the analysts said, "The data to date for the Rett syndrome gene therapies from NGNE and TSHA seem messy to us, and closer to Elevidys than a 'parachute'.
- Baird analysts have also cut price target for the company to $24 from previous $38.
- The stock is down 11.7% so far today.
More on Neoleukin Therapeutics
- Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401
- Neurogene GAAP EPS of -$1.08 misses by $0.02
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
- Seeking Alpha’s Quant Rating on Neoleukin Therapeutics
- Historical earnings data for Neoleukin Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
